Low-calorie sweetener linked to liver disease: new study warns of hidden risk

Show summary Hide summary

• Study shows a hidden path from sugar to liver fat
• What sorbitol is and why it’s used in foods
• Gut bacteria act as first responders for sorbitol
• How fructose drives fatty liver disease
• Experts urge caution interpreting fish data
• Signs, testing and what doctors look for
• Managing risk and treatment options
  • Practical takeaways for consumers

A new study raises fresh questions about a familiar ingredient in sugar-free gums and diet treats. Researchers found that the sugar alcohol sorbitol, widely used as a low-calorie sweetener, may set off a chain of events that ends with fat building up in the liver.

Study shows a hidden path from sugar to liver fat

Scientists at Washington University in St. Louis tested how the body handles glucose when gut microbes are reduced. They gave adult zebrafish antibiotics to wipe out most intestinal bacteria. Then they followed how the animals processed sugar.

With fewer microbes to break things down, the fish produced and retained higher amounts of sorbitol. That compound did not stay in the gut. It traveled to the liver, where it was converted into a form of fructose.

The key finding: when gut bacteria can’t degrade sorbitol fast enough, the compound accumulates and moves to the liver, potentially feeding processes that promote fatty liver disease.

What sorbitol is and why it’s used in foods

Sorbitol is a naturally occurring sugar alcohol found in apples, pears, peaches and other fruits. Food makers also manufacture it for use in sugar-free and reduced-calorie products.

• Sorbitol delivers sweetness at about 60% of table sugar.
• It has roughly 35% fewer calories per gram than sugar.
• It helps retain moisture and texture in processed foods.

Because of these advantages, sorbitol appears in thousands of products worldwide. The body can also make sorbitol internally when glucose levels rise. That biological route has tied sorbitol to diabetes and blood sugar research for years.

Gut bacteria act as first responders for sorbitol

Under normal conditions, intestinal microbes break down modest amounts of sorbitol into harmless byproducts. This keeps levels manageable after meals or fruit consumption.

But if the microbial community is disrupted or the sorbitol load is large, breakdown falls behind production. In the Washington University experiments, antibiotics removed the microbes that normally process sorbitol.

When the microbes are gone or overwhelmed, sorbitol passes from the gut to the liver. There, enzymes convert it into fructose, a sugar known to promote lipid buildup.

How fructose drives fatty liver disease

Fructose is metabolized differently from glucose. The liver readily converts excess fructose to fat. Over time, that fat accumulates in liver cells.

That process is linked to metabolic dysfunction-associated steatotic liver disease, or MASLD. The condition used to be called nonalcoholic fatty liver disease.

• Fat accumulation leads to inflammation.
• Chronic inflammation causes scarring and tissue damage.
• Advanced cases can progress to cirrhosis or liver cancer.

MASLD is already common: roughly one in three U.S. adults shows signs of the disease, and rates are rising among children.

Experts urge caution interpreting fish data

Not everyone accepts the study as a direct warning for humans. Critics note key limitations.

Carla Saunders, head of the Calorie Control Council, said fish models don’t always translate to human biology. She added that global food authorities have long deemed sorbitol safe when used appropriately.

Still, authors argue the experiments highlight a biological route that could operate in people, especially when gut bacteria are disrupted or when diets load the gut with sugar and sugar alcohols.

Signs, testing and what doctors look for

MANY people with MASLD have no obvious symptoms. Early signs are subtle and often dismissed.

• Fatigue or milder-than-usual tiredness.
• Vague discomfort or fullness in the upper right abdomen.
• Abnormal liver enzymes on routine bloodwork.

Because symptoms are nonspecific, clinicians usually detect MASLD through blood tests or imaging done for other reasons. A provider will also check for metabolic risk factors:

• Overweight or obesity
• Type 2 diabetes or prediabetes
• High blood pressure
• High cholesterol

Managing risk and treatment options

Early-stage MASLD responds best to lifestyle changes. Weight loss, regular exercise and blood sugar control can reduce liver fat and inflammation.

Drug therapy for MASLD is limited. However, two medications now address metabolic dysfunction–associated steatohepatitis, the more severe form:

• Rezdiffra (resmetirom): developed to target liver fat and inflammation.
• Wegovy (semaglutide): a GLP-1 receptor agonist that aids weight loss and metabolic control.

Experts stress these medicines are intended to complement, not replace, diet and lifestyle changes.

Practical takeaways for consumers

• Be mindful of processed foods and sugar alcohols if you have metabolic risk factors.
• Don’t assume a sugar-free label eliminates all metabolic risks.
• Talk with a clinician about testing if you have risk factors or unexplained abnormal liver tests.
• Consider dietary patterns that support a healthy gut microbiome.